A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer

Pancreas

Volumn 30, Issue 3, 2005, Pages 206-210

  Takahashi, Yutaka ^a,c   Mai, Masayoshi ^a   Sawabu, Norio ^a   Nishioka, Kenji ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b Nishioka Consulting   (United States)

^c NONE   (Japan)

Author keywords

Gemcitabine; Pancreas cancer; Tailored dose chemotherapy; Time to progressive disease

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; FEMALE; HUMAN; INDIVIDUALIZED MAXIMUM REPEATABLE DOSE; MALE; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PILOT STUDY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; TUMOR VOLUME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 15444379311     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000153335.73352.c7     Document Type: Article

References (22)

1. Takahashi Y, Nishioka K. Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst. 1995;87:1262-1263.
2. Takahashi Y, Mai M, Taguchi T, et al. Prolonged stable disease effects survival in patients with solid gastric tumor: analysis of phase II studies of doxifluridine. Int J Oncol. 2000;17:285-289.
3. Schanall SF, Macdonald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol. 1996;23:220-228.
4. Burns HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
5. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;147:207-214.
6. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreas cancer. J Clin Oncol. 2002;20:1182-1191.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
8. Mikulski SM, Chun HG, Mittelman A, et al. Relationship between response rate and median survival in patients with advanced non-small cell lung cancer: comparison of ONCONASE with other anticancer agents. Int J Oncol. 1995;6:889-897.
9. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet. 2000;356:373-378.
10. John R, Johnson R, Williams G, et al. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2002;21:1404-1411.
11. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998; 101:847-854.
12. Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer. 2003;89:1837-1842.
13. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29-34.
14. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101-105.
15. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353.
16. Crino L, Mosconi AM, Calandri C, et al. Gemcitabine in advanced pancreatic cancer: a phase II trial. Am J Clin Oncol. 2001;24:296-298.
17. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3,000 patients with pancreatic carcinoma. Cancer. 1999;85:1261-1268.
18. Rosemurgy A, Buckels J, Charnley R, et al. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc Am Soc Clin Oncol. 1999;18:261a.
19. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3296-3302.
20. Humblet Y, Van Cutsem E, Dubois C, et al. Compassionate use of Gemzar in advanced pancreatic cancer: a Belgian experience. Acta Gastroenterol Belg. 2001;64:305-308.
21. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384-1391.
22. Takahashi Y, Sakamoto J, Takeuchi T, et al. A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy. Jpn J Clin Oncol. 2004;34:342-345.